CSOP Hang Seng Biotech ETF(03174.HK) closed down 0.85%, latest price at HK$3.520
Newtimespace News, as of the close on April 27, CSOP Hang Seng Biotech ETF(03174.HK) finished at HK$3.520, down 0.85%. The ETF opened at HK$3.532, reached a high of HK$3.538, and touched a low of HK$3.512. The latest trading volume was 402,300 units, with a latest turnover of approximately HK$1.4185 million, and assets under management of approximately HK$901 million.
CSOP Hang Seng Biotech ETF(03174.HK) tracks the Hang Seng Biotech Index, which is compiled and published by Hang Seng Indexes Company Limited. The index aims to track the overall performance of the 30 largest biotech companies listed in Hong Kong that are eligible for Stock Connect trading. Its constituent stocks cover four business sub-categories: pharmaceuticals, biotechnology, drug distribution, and medical equipment and supplies, focusing on core biotech areas such as innovative drugs, CXO, and medical devices. The index provides investors with a high-purity tool for concentrated investment in Hong Kong-listed biotech leaders and capturing the development trends of pharmaceutical innovation.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- PINESTONE (00804.HK): Net Proceeds of HKD 24.2 Million from Placing for Virtual Asset Licence Application and AI Application Expansion
- MICROTECH MED-B (02235.HK): Enters Raw Material Purchase Framework Agreement with Connected Person Hangzhou Shukang
- DETAI NEWENERGY (00559.HK): Enters Memorandum of Understanding for Proposed Acquisition of HKD 505 Million; Trading Remains Suspended
- SCIENTECH (02291.HK): Acquires 54.2384% Equity of Shanghai Minwei Biotechnology for RMB 1.088 Billion, Constituting Major and Connected Transaction
- CHINAHONGQIAO (01378.HK): Revises Annual Caps under Industrial Products Purchase Agreement, 2027 Cap Raised to RMB 26.24 Million